B.C.I. Pharma – Trademark Portfolio
Entity Type: 98
B.C.I. Pharma holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 5 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include HIRUNDO.
Avenue de l’Hôpital 11
B-4000 Liège
Showing of trademarks Trademarks
Trademark Classifications
B.C.I. Pharma's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does B.C.I. Pharma have?
B.C.I. Pharma has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does B.C.I. Pharma file in?
B.C.I. Pharma files trademarks across 5 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.
What are B.C.I. Pharma's most well-known trademarks?
B.C.I. Pharma's registered trademark portfolio includes well-known marks such as HIRUNDO. These are among 1 currently registered trademark in the portfolio.
What is B.C.I. Pharma's trademark registration success rate?
B.C.I. Pharma has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.